# Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

> **NCT02249130** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir (TPV)
- **DRUG:** Ritonavir (RTV)
- **DRUG:** Delavirdine (DLV)
- **DRUG:** Zidovudine (ZDV)
- **DRUG:** Lamivudine (3TC)
- **DRUG:** Stavudine (d4T)

## Key facts

- **NCT ID:** NCT02249130
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2000-04
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249130, "Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02249130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*